Ropes & Gray advised Galderma on the deal, while Latham & Watkins advised ALASTIN. Galderma, one of the world’s largest independent dermatology companies, executed its acquisition...
Galderma’s Acquisition of Alastin Skincare
Waldencast’s $1.2 Billion Business Combination With Obagi and Milk Makeup
Skadden, Arps, Slate, Meagher & Flom represented Waldencast. Latham & Watkins, working alongside Conyers and Nixon Peabody, represented Obagi, and Goodwin Procter represented Milk Makeup in...
Thorne HealthTech’s $70 Million Initial Public Offering
Wilson Sonsini Goodrich & Rosati represented Thorne HealthTech, while Latham & Watkins represented the underwriters in the offering. Thorne HealthTech, a leader in developing innovative solutions...
Icosavax’s $209.3 Million IPO
Latham & Watkins represented Icosavax, while Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its...
Janux Therapeutics’ $193.8 Million IPO
Wilson Sonsini Goodrich & Rosati advised Janux Therapeutics, Inc. on the deal, while Latham & Watkins LLP represented the underwriters. Janux Therapeutics, Inc., a biopharmaceutical company...
eFFECTOR Therapeutics’ Merger with Locust Walk Acquisition Corp.
Latham & Watkins LLP represented eFFECTOR in the transaction, eFFECTOR Therapeutics, Inc. (eFFECTOR), a biopharmaceutical company focused on pioneering the development of selective translation regulation inhibitors...
J.C. Flowers & Co and Bain Capital Credit’s Purchase Of An Equity Stake In The Co-operative Bank
Macfarlanes has advised J.C. Flowers & Co and Bain Capital Credit on the deal. J.C. Flowers & Co and Bain Capital Credit acquired an equity stake in The...
Reneo Pharmaceuticals’ $93.8 Million Initial Public Offering
Latham & Watkins LLP represents the underwriters in the offering while Wilson Sonsini Goodrich & Rosati advised Reneo Pharmaceuticals, Inc. Reneo Pharmaceuticals, Inc. has announced the pricing...
Affidea Group’s Acquisition Of Fortius Clinic
Macfarlanes has advised Affidea Group on the deal. Osborne Clarke has advised the shareholders of Fortius Group Limited. Affidea Group, the leading European provider of diagnostic...